Israel - hebreu - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 10 mg - octreotide

Israel - hebreu - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 20 mg - octreotide

Israel - hebreu - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 30 mg - octreotide

Israel - hebreu - Ministry of Health

medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 10 mg/vial - pasireotide

Israel - hebreu - Ministry of Health

medison pharma ltd - pasireotide as pamoate - אבקה וממס להכנת תרחיף להזרקה - pasireotide as pamoate 30 mg/vial - pasireotide

Israel - hebreu - Ministry of Health

astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Israel - hebreu - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Israel - hebreu - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Israel - hebreu - Ministry of Health

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Israel - hebreu - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate - קנים להשתלה - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).